UK markets close in 5 hours 8 minutes

Guardant Health, Inc. (GH)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
109.35-0.17 (-0.16%)
At close: 4:00PM EDT
109.35 0.00 (0.00%)
Pre-market: 05:34AM EDT
Sign in to post a message.
  • R
    Richard
    This stock was trading consistently between $160 to $180 just 6 to 8 months ago. They had so much promise with Luna -1 and Luna -2 with a TAM of $45B+. It is now hard to see this stock reaching these levels unless we hear about possible FDA approvals. I have been holder of this stock since shortly after IPO. So much promise then and still does. Need to do more DD as to what is happening as I have been to complacent.
  • K
    Kevin
    I have had them since shortly after the IPO. I bought more when they went up to $100's and came back down to low $60's. The basic premise of the company has not changed. Lunar approvals are coming. the management is checking all the boxes per their plan. Nothing has changed except COVID created delays in revenue growth based on existing products due to cancer patients, with compromised immune systems due to drug therapies, have not been going to hospitals or doctors as often as before. Everything else is noise. Short term holders of this stock are doomed due to low volume. Stock price has been affected by insider selling (don't blame them, most of their compensation is through stocks) and pre IPO holders. It will sift through. We will be back on track towards $200/share.
  • Y
    Yahoo Finance Insights
    Guardant Health is up 5.88% to 105.29
  • A
    AARON
    According to Bloomberg, deal NOT happening.
  • R
    Rich
    Truly time the CEO departed and the sooner the better !!!!!
  • W
    Wee
    What triggered this sell off?
  • F
    Frank
    Time to go back up
  • K
    Kevin
    The sell off with such a large volume and the subsequent day, yesterday, however, were important events as it established a very firm bottom at $105 for GH. Barring any extraordinary event, it is up from here.
  • K
    Kevin
    Complete knee jerk reaction to the news since it is not confirmed, assuming it is true, no one knows how much premium they would pay for Neo. Thus a 16% drop makes no sense other than just an initial reaction. Assume they pay no premium, then it's net net neutral since they add valuation to the company while assuming debt. Neo has positive EPS, so, in fact it would be accretive to their business - then share price of the combined company should rise not go down - if no premium paid.
    Long term it is a good play against Grail /Illumina. But they must show the ability to execute the assumed synergies if they do acquire them. That is the risk.
  • K
    Kevin
    Despite pretty severe market movements, GH is holding very well.
  • K
    Kevin
    As I said, $105 is a very firm bottom due to Friday and Monday actions
  • K
    Kevin
    steady everyone; $120's will be captured again. Then earnings report. They need to show growth in top line revenue; no need for profits to go crazy. Just decent top line revenue growth. IF they show anything over 15% QoQ growth on top line revenue; we will see $150's by year end.
  • R
    Rich
    How about a class action lawsuit!!!!!!
  • s
    soflagrtwht
    This could be very bad for GH shareholders, here's 2 tidbits to consider. First, in MBA class for M&A, the first rule is you never buy a company with a lower valuation that yours. NEO's P/S is 1/3 of GHs. Buying less valuable companies reduces your value. Second, remember EXAS buying a genomic company about 1.5-2 yrs ago? Same story, and EXAS has never recovered. So, on the basis of good M&A, and the basis of past acquisitions, this is a bad deal for GH and GH shareholders.
  • K
    Kevin
    Trying to manipulate this stock, you need to buy and sell over 5,000 shares. 2 shares won't do!! Haha.
  • j
    jim
    Based on my assessment, they really need to lay off 200 people and either save that money or hire people who know what they are doing. You got two fat cats on the top who just don't care and they have hired family and friends at Director and VP jobs and those guys brought in more of their buddies on board.
    Enough said...you guys get the point.
  • F
    Frank
    What’s happening? Inside / investors bigger sell off?
  • K
    Kevin
    Instead of that acquisition move, while the stock had momentum in $130's, they should've announced ORACLE. By now, we would be looking into $140's.
    Somewhat disappointing; amateur management when it comes to managing the stock price and publicity.
  • m
    mccrystal
    They had some interesting insights about GH on (http://Fairstox.com). Definitely made me think twice about the company.
  • J
    James
    Target price of over $167? The 52 week low is like $96.66, or some $6 away. Which comes first, a new target, or a new low. I think the down side wins. .